235 related articles for article (PubMed ID: 28885538)
1. Clinical relevance of 18F-FDG PET/CT lower-limb imaging in patients with malignant cutaneous melanoma.
Plouznikoff N; Arsenault F
Nucl Med Commun; 2017 Dec; 38(12):1103-1108. PubMed ID: 28885538
[TBL] [Abstract][Full Text] [Related]
2. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
Querellou S; Keromnes N; Abgral R; Sassolas B; Le Roux PY; Cavarec MB; Le Duc-Pennec A; Couturier O; Salaun PY
Nucl Med Commun; 2010 Sep; 31(9):766-72. PubMed ID: 20585271
[TBL] [Abstract][Full Text] [Related]
3. Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma.
Lazaga FJ; Oz OK; Adams-Huet B; Anderson J; Mathews D
Clin Nucl Med; 2013 Nov; 38(11):882-4. PubMed ID: 24096999
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma.
Niederkohr RD; Rosenberg J; Shabo G; Quon A
Nucl Med Commun; 2007 Sep; 28(9):688-95. PubMed ID: 17667747
[TBL] [Abstract][Full Text] [Related]
5. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?
Tan JC; Chatterton BE
Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
8. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
[TBL] [Abstract][Full Text] [Related]
10.
Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
12. Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography?
Iagaru A; Quon A; McDougall IR; Gambhir SS
Mol Imaging Biol; 2006; 8(4):212-7. PubMed ID: 16724293
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of FDG PET/CT of the Lower Extremities in Patients With Merkel Cell Carcinoma With Primary Disease Site Outside of the Lower Extremities.
Ishiyama M; Behnia F; Vesselle H
AJR Am J Roentgenol; 2021 Mar; 216(3):776-780. PubMed ID: 33474987
[No Abstract] [Full Text] [Related]
14. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
[TBL] [Abstract][Full Text] [Related]
15. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
[TBL] [Abstract][Full Text] [Related]
16. FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results.
Mercier GA; Alavi A; Fraker DL
Clin Nucl Med; 2001 Oct; 26(10):832-6. PubMed ID: 11564919
[TBL] [Abstract][Full Text] [Related]
17. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal studies of the
Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898
[TBL] [Abstract][Full Text] [Related]
19. Metabolic assessment of Merkel cell carcinoma: the role of 18F-FDG PET/CT.
Ben-Haim S; Garkaby J; Primashvili N; Goshen E; Shapira R; Davidson T; Israel O; Epelbaum R
Nucl Med Commun; 2016 Aug; 37(8):865-73. PubMed ID: 27092665
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
